Loading company…
Tourmaline Bio develops medicines for immune diseases, including thyroid eye disease.
Founded in 2021, Tourmaline Bio is based in New York, US. It is developing the anti-IL-6 antibody TOUR006 for thyroid eye disease and atherosclerotic cardiovascular disease. The company was co-founded by Sandeep Kulkarni, MD, and Caley Castelein, MD. In January 2024, it raised USD 150 million in a private placement, selling 4.62 million shares at USD 32.50 per share on the Nasdaq Global Select Market.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in